RT Journal Article
SR Electronic
T1 Association Between CD133 Expression and Prognosis in Human Lung Adenocarcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 905
OP 910
DO 10.21873/anticanres.14843
VO 41
IS 2
A1 YAMASHITA, NAOKI
A1 OYAMA, TSUNEHIRO
A1 SO, TETSUYA
A1 MIYATA, TAKEAKI
A1 YOSHIMATSU, TAKASHI
A1 NAKANO, RYUJI
A1 MATSUNAGA, WATARU
A1 GOTOH, AKINOBU
YR 2021
UL http://ar.iiarjournals.org/content/41/2/905.abstract
AB Background/Aim: CD133 is a promising candidate marker for cancer stem cells. However, clinical studies on CD133 expression in human lung adenocarcinoma have not yet been conducted. We hypothesized that CD133 expression in lung adenocarcinoma is a poor prognostic factor. Patients and Methods: CD133 expression in lung adenocarcinoma was examined clinicopathologically. Then, clinicopathological parameters and patient prognosis were investigated. Moreover, CD133 expression was examined via immunohistochemical staining, and the relationship between CD133 expression and clinicopathological parameters was explored. Results: Approximately 48.0% (49/102) of patients had CD133-positive cells. Based on a subgroup analysis, the CD133-positive group with pStage I+II disease had a significantly worse disease-free interval than the CD133-negative group (p<0.05). Conclusion: CD133 expression may be a poor prognostic factor in lung adenocarcinoma.